Treatment-Resistant Depression (TRD)
Treatment-Resistant Depression (TRD) Market

Treatment-resistant depression is a major depressive disorder (MDD) that doesn't respond to traditional and first-line therapeutic options. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest. Depression lasting a minimum of 2 weeks besides meeting about five or more of the DSM-V criteria (of MDD) is considered as MDD. Further, those with a minimum of one episode within the prior 12 months are classified as 12-month MDD.


Treatment-Resistant Depression Epidemiological Segmentation

The Epidemiological Segmentation of Treatment-Resistant Depression in 7MM from 2017 to 2030 is segmented as:-

  • Total Diagnosed Prevalent Cases of Treatment-Resistant Depression  
  • Gender-Specific Cases of Treatment-Resistant Depression
  • Age-Specific Prevalent Cases of Treatment-Resistant Depression


Treatment-Resistant Depression Epidemiology

  • The total prevalent population of Treatment-Resistant Depression in 7MM in 2018 was 4,464,781 
  • The total number of TRD prevalent cases in the United States was found to be 3,083,238.
  • Germany had 233,432 Treatment-Resistant Depression cases.
  • The total number of TRD cases in the United Kingdom was estimated to be 570,56.
  • The total Treatment-Resistant Depression prevalent cases in Italy were 45,641.
  • In Japan, the total number of TRD prevalent cases was observed to be 256,492.

 

Treatment-Resistant Depression Market

The therapeutic market size of Treatment-Resistant Depression in 7MM in 2017 was USD 1,736.4 million.

 

Treatment-Resistant Depression Market Drivers

  • Retainment of current management strategies
  • Refined clinical trial design
  • Development of pioneering therapies

 

Treatment-Resistant Depression Market Barriers

  • Economic Burden
  • Variable treatment response
  • Commercial challenges 

 

Treatment-Resistant Depression Emerging Drugs

The emerging drugs of the TRD market are:

  • ALKS 5461
  • Cariprazine
  • Pimavanserin
  • AXS-05
  • Seltorexant
  • Esketamine DPI
  • REL-1017
  • AV-101
  • MIJ821
  • Psilocybin (COMP360)

and many others.


Treatment-Resistant Depression Key Players

The key players in the TRD market are:

  • Alkermes
  • Allergan/Gedeon Richter’s
  • ACADIA Pharmaceuticals
  • Axsome Therapeutics
  • Johnson and Johnson/Minerva Neurosciences
  • Celon Pharma
  • Relmada Therapeutics
  • VistaGen Therapeutics
  • Novartis
  • COMPASS Pathways

and many others.